These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 34986284)

  • 41. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study.
    Scheinberg P; Wu CO; Nunez O; Scheinberg P; Boss C; Sloand EM; Young NS
    Haematologica; 2009 Mar; 94(3):348-54. PubMed ID: 19181786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
    Rubio-San-Simón A; Lázaro Rodríguez I; Vázquez Gómez F; Vivanco Martínez JL; Pérez Alonso V
    An Pediatr (Engl Ed); 2019 Apr; 90(4):246-247. PubMed ID: 29798814
    [No Abstract]   [Full Text] [Related]  

  • 43. Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study.
    Peffault de Latour R; Huynh L; Ivanova JI; Totev T; Bilginsoy M; Antin J; Roy A; Duh MS
    Ann Hematol; 2020 Apr; 99(4):743-752. PubMed ID: 32065291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia.
    Zhang F; Zhang L; Jing L; Zhou K; Wang H; Peng G; Li Y; Li Y; Li J; Ye L; Shi L; Fan H; Zhao X; Chu Y; Hao Y; Wang J
    Exp Hematol; 2013 Apr; 41(4):328-34. PubMed ID: 23313080
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy.
    Hwang YY; Chan TSY; Chan FHY; Lau CWP; Luk YY; Lau GWN; Chan KP; Leung KH; Kho B; Lau JSM; Lau CK; Mak V; Yip SF; Lin SY; Sim JPY; Kwong YL
    Ann Hematol; 2022 Jun; 101(6):1163-1172. PubMed ID: 35412083
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of eltrombopag in aplastic anemia in Europe.
    Ecsedi M; Lengline É; Knol-Bout C; Bosman P; Eikema DJ; Afanasyev B; Maschan A; Dreger P; Halkes CJM; Drexler B; Cortelezzi A; Drénou B; Patriarca A; Bruno B; Onofrillo D; Lanino E; Pulanic D; Serventi-Seiwerth R; Garnier A; Ljungman P; Bonifazi F; Giammarco S; Tournilhac O; Pioltelli P; Rovó A; Risitano AM; de Latour RP; Dufour C; Passweg J;
    Ann Hematol; 2019 Jun; 98(6):1341-1350. PubMed ID: 30915499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deficit of circulating CD19
    Zaimoku Y; Patel BA; Kajigaya S; Feng X; Alemu L; Quinones Raffo D; Groarke EM; Young NS
    Br J Haematol; 2020 Aug; 190(4):610-617. PubMed ID: 32311088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Eltrombopag combined with cyclosporine alone for treatment of very severe aplastic anemia: a case report].
    Cheng H; Wang X; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):612. PubMed ID: 32397030
    [No Abstract]   [Full Text] [Related]  

  • 49. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
    Geng W; Kearney S; Nelson S
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.
    Aslanis V; Zhang J; Lomeli B; Grosch K; Ouatas T
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):847-855. PubMed ID: 30171280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group.
    Kamio T; Ito E; Ohara A; Kosaka Y; Tsuchida M; Yagasaki H; Mugishima H; Yabe H; Morimoto A; Ohga S; Muramatsu H; Hama A; Kaneko T; Nagasawa M; Kikuta A; Osugi Y; Bessho F; Nakahata T; Tsukimoto I; Kojima S;
    Haematologica; 2011 Jun; 96(6):814-9. PubMed ID: 21422115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A rare side effect: eltrombopag associated hyperpigmentation.
    Atay H; Kelkitli E; Turgut M
    G Ital Dermatol Venereol; 2020 Dec; 155(6):803-804. PubMed ID: 31104458
    [No Abstract]   [Full Text] [Related]  

  • 53. Eltrombopag: a review of its use in patients with severe aplastic anaemia.
    McCormack PL
    Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.
    Zhang Y; Li J; Li X; Geng Q; Xie Y; Zhang G; Wei M; Ma Y
    Syst Rev; 2024 Apr; 13(1):101. PubMed ID: 38576005
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia.
    Shinn LT; Benitez LL; Perissinotti AJ; Reid JH; Buhlinger KM; van Deventer H; Barth D; Wagner CB; Zacholski K; Desai R; Soule A; Stump SE; Weis TM; Bixby D; Burke P; Pettit K; Marini BL
    Int J Hematol; 2023 Dec; 118(6):682-689. PubMed ID: 37882977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children.
    Jeong DC; Chung NG; Cho B; Zou Y; Ruan M; Takahashi Y; Muramatsu H; Ohara A; Kosaka Y; Yang W; Kim HK; Zhu X; Kojima S
    Haematologica; 2014 Apr; 99(4):664-71. PubMed ID: 24213150
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults.
    Zhu X; Guan J; Xu J; Wei J; Jiang L; Yin J; Zhao L; Zhang Y
    Blood Cells Mol Dis; 2014 Sep; 53(3):157-60. PubMed ID: 24931461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term follow-up study of porcine anti-human thymocyte immunoglobulin therapy combined with cyclosporine for severe aplastic anemia.
    Chen M; Liu C; Zhuang J; Zou N; Xu Y; Zhang W; Li J; Duan M; Zhu T; Cai H; Cao X; Wang S; Zhou D; Han B
    Eur J Haematol; 2016 Mar; 96(3):291-6. PubMed ID: 25996247
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia.
    Zhang W; Chang LX; Zhao BB; Zheng Y; Shan DD; Tang BH; Yang F; Zhou Y; Hao GX; Zhang YH; van den Anker J; Zhu XF; Zhang L; Zhao W
    J Clin Pharmacol; 2024 Aug; 64(8):932-943. PubMed ID: 38497347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy and safety analysis of eltrombopag and recombinant human thrombopoietin combined with immunosuppressive therapy for severe aplastic anemia].
    Yuan FF; Zhang QL; Zhang LN; Xiong YY; Li MJ; Zhou H; Wei XD; Liu XJ; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):1021-1024. PubMed ID: 35045674
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.